ARTICLE | Clinical News
ProstVac: Ph I/II started
April 20, 2017 9:50 PM UTC
Bavarian Nordic said NCI investigators began an open-label, U.S. Phase I/II trial to evaluate ProstVac plus Opdivo nivolumab and Yervoy ipilimumab in about 65 patients. The Phase I portion will enroll...
BCIQ Target Profiles